UK government lays out life science investment plans Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 24 June, 2025

sponsored by Oncology Drugs to Watch: Top takeaways from ASCO 2025 Clarivate oncology experts deliver clear, strategic insights on 13 major drugs from ASCO 2025. Learn what the latest data means for the future of cancer treatment and drug development. Download the report

presented by Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

spotlight Who are the women reshaping biopharma R&D? Nominate them for Endpoints' annual report

news Nuvalent closes in on FDA filing for lung cancer drug with topline Phase 1/2 data Updated: Amgen plans lower, slower MariTide doses for obesity drug’s Phase 3 UK government blueprints ambition to be a key life sciences hub  Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3

Jun 24 10:30am ET Expanding access, accelerating trials: The power of community-based oncology research sponsored by START Research Jun 26 11:00am ET May the (Power of the) Pool be with you: Accelerating time from DNA to GMP – STI based CLD Platform sponsored by Rentschler Biopharma Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trials sponsored by Precision for Medicine Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Supply chain strategy just got more complicated — is your manufacturing model still viable? Trade tensions, policy shifts, and geopolitical uncertainty have biopharma executives rethinking manufacturing and distribution. How are the experts doing it now? Find out — get your spot today.

ENDPOINTS PHARMA The politics of vaccination take center stage as RFK Jr.’s rebuilt CDC panel is set to meet AstraZeneca, Daiichi Sankyo gain lung cancer indication for Enhertu successor Acting CDER chief is leaving after almost nine years at FDA Novo ends short-lived partnership with Hims over compounded obesity drugs Supreme Court asks DOJ to weigh in on Hikma ‘skinny label’ fight against Amarin Illumina to buy SomaLogic for $350M, pushing further into proteomics

in case you missed it 1. Exelixis' positive Phase 3 colorectal cancer data boost stock 2.